Pfizer, BioNTech to supply 200M doses of COVID-19 vaccine in Europe

• Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have reached an agreement with the European Commission (EC) to supply 200M doses of their investigational BNT162b2 mRNA-based vaccine candidate against COVID-19, with an option for the EC to request an additional 100M doses.
• Deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.
• “Today’s finalized supply agreement with the European Commission represents the largest initial order of vaccine doses for Pfizer and BioNTech to date and a major step toward our shared goal of making a COVID-19 vaccine available to vulnerable populations,”  said Albert Bourla, Chairman and CEO, Pfizer..
• Pfizer and BioNTech announced the conclusion of exploratory talks with EC on September 9, 2020. The proposed supply agreement is now final.
• On November 9, PFE and BNTX announced their mRNA-based vaccine candidate, BNT162b2, against COVID-19 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of infection, based on the first interim efficacy analysis.
• Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.
• https://seekingalpha.com/news/3634826-pfizer-biontech-to-supply-200m-doses-of-mrna-based-covidminus-19-vaccine-in-europe